From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MK-4409 structure.svg
Clinical data
ATC code
  • None
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
Molar mass406.46 g·mol−1
3D model (JSmol)

MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.[1][2]

See also[edit]


  1. ^ Chobanian, Harry R.; Guo, Yan; Liu, Ping; Chioda, Marc D.; Fung, Selena; Lanza, Thomas J.; Chang, Linda; Bakshi, Raman K.; Dellureficio, James P.; Hong, Qingmei; McLaughlin, Mark; Belyk, Kevin M.; Krska, Shane W.; Makarewicz, Amanda K.; Martel, Elliot J.; Leone, Joseph F.; Frey, Lisa; Karanam, Bindhu; Madeira, Maria; Alvaro, Raul; Shuman, Joyce; Salituro, Gino; Terebetski, Jenna L.; Jochnowitz, Nina; Mistry, Shruti; McGowan, Erin; Hajdu, Richard; Rosenbach, Mark; Abbadie, Catherine; et al. (2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–721. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
  2. ^ Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.

External links[edit]